COMP <GO>
QGEN vs TECH // GROSS PROFIT MARGIN
Qiagen N.V. (NYSE) VS. Bio-Techne Corp (NASDAQ) • 15-METRIC TALLY: QGEN 11
— TECH 3
▲ GROSS PROFIT MARGIN LEADER: TECH
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
gross-margins
62.20%
LAST: $72.66 (-0.07%) • MKT CAP: $11.40B
gross-margins
64.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. TECH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | TECH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 62.20% | 64.80% | -2.60 | TECH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 3.40% | +4.60 | QGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 91.3x | -73.70 | QGEN | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 2.25% | +2.12 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | 8.40% | +13.90 | QGEN | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 6.00% | +14.30 | QGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 5.20% | +0.50 | QGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 0.44% | +0.08 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 7.12 | -3.58 | TECH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.4 | 59.3 | +13.10 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.88 | +0.07 | QGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | 140.0x | -117.30 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.37B | $11.40B | -$1.03B | TECH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | TECH REV | QGEN GROSS % | TECH GROSS % | QGEN FCF | TECH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $1.22B | 62.2% | 64.8% | $453.3M | $256.6M |
| FY 2024 | $1.98B | $1.16B | 48.9% | 66.4% | $506.4M | $236.1M |
| FY 2023 | $1.97B | $1.14B | — | — | $371.0M | $203.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
TECH // BETA 0.88